BNR:NSD-Burning Rock Biotech Limited (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 36.10

Change

-0.55 (-1.50)%

Market Cap

USD 3.74B

Volume

0.73M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 13 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen Plus that targets therapy and immunotherapy, as well as immunotherapy- related biomarkers, such as microsatellite instability and tumor mutation burden, and NTRK fusions; and LungPlasma, a circulating tumor DNA liquid biopsy- based test for non-small cell lung cancer. It also offers ColonCore for testing gastrointestinal cancers; and HRDCore for testing genes associated with homologous recombination deficiency. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with major pharmaceutical companies, including AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone Pharmaceuticals, and BeiGene primarily through central laboratory and companion diagnostics development services to pharmaceutical companies. The company was founded in 2014 and is headquartered in Guangzhou, China. Address: Building 3, Standard Industrial Unit 2, Guangzhou, China, 510300

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-04 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

-16.80 (-4.03%)

USD60.75B 93.58 57.27
IDXX IDEXX Laboratories, Inc

-12.17 (-2.44%)

USD42.54B 74.22 54.56
DXCM DexCom, Inc

-12.43 (-3.37%)

USD35.46B 72.87 99.23
EXAS Exact Sciences Corporation

-5.55 (-4.38%)

USD21.40B N/A N/A
GH Guardant Health, Inc

-10.55 (-7.34%)

USD14.43B N/A N/A
OZON Ozon Holdings PLC

-3.83 (-6.36%)

USD12.27B N/A N/A
NTRA Natera, Inc

-6.55 (-6.03%)

USD9.41B N/A N/A
PRAH PRA Health Sciences, Inc

-1.93 (-1.33%)

USD9.27B 47.25 24.16
ICLR ICON Public Limited Company

-2.95 (-1.69%)

USD9.24B 28.45 19.18
SYNH Syneos Health, Inc

-2.15 (-2.91%)

USD7.70B 40.34 21.29

ETFs Containing BNR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 56.28% 88% B+ 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.28% 88% B+ 92% A-
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 3.74B 73% C 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 95% A 94% A
Price/Book Ratio 9.54 38% F 21% F
Price / Cash Flow Ratio -16.39 71% C- 79% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 28.82% 94% A 94% A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio -2.05% 93% A 93% A
Technical Ratios  
Short Ratio 0.85 67% D+ 68% D+
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector